Company Overview
Our Mission: At Esperion, we are working tirelessly to deliver innovative medicines that help patients reach their goals today, tomorrow, and into the future. Esperion is a fully remote-based company with a corporate headquarters located in Ann Arbor, MI. The Company offers a competitive salary including a performance-based bonus program and stock-based compensation, a comprehensive benefits package including a 401(k) matching plan and health insurance, and paid time off and holidays.
Position Title: Manager/Senior Manager - Financial Planning and Analysis
The Manager/Senior Manager, Financial Planning and Analysis will be the financial business partner for the assigned business unit(s) supporting senior leadership and their respective organizations. This position will provide financial analysis and partner with the assigned business unit(s) to perform operations planning, financial forecasting, budget-to-actual variance reporting, and financial modeling. The candidate for this role will collaborate with cross-functional teams, engage in market analysis, and make data-driven recommendations to maximize the overall performance. This position will report to the Senior Director, Financial Planning and Analysis.
Preferred Location: Remote
Essential Duties and Responsibilities
Additional Duties and Responsibilities as Assigned
Qualifications (Education & Experience)
At ESPERION, we’re committed to changing that. Read about our mission and our core values.
We have assembled a world-renowned team of lipid specialists who have been at the forefront of innovation in lipid management for decades.
Our goal: to help patients who still need additional lipid lowering despite taking maximally tolerated statin therapy. With this goal in mind, we are driven to provide patients a novel treatment that not only works to lower LDL-C, but also works safely within their bodies.
Every day, we are focused on this lone objective. Because we believe that to change this treatment paradigm, our company would rather be excellent in just this one disease state, than be good in several.
Our approach is unprecedented in modern pharmaceuticals, and we think it is the right one.